Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 9:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 20,940 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immune System Disease Clear all
Completed Not applicable Interventional

Study of A Cell-Phone System to Improve Health of Youth With Diabetes

NCT02280564
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
health coaching with technology support
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 16 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Aurora, Colorado • Raleigh, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PrEP Readiness Interventions for Supporting Motivation

NCT04205487
View directory record Official record
Conditions
HIV Infections, Pre-exposure Prophylaxis, Substance Use Disorders
Interventions
Motivational Interviewing (MI), Contingency Management (CM)
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation

NCT00990249
View directory record Official record
Conditions
Leukemia, Lymphoma, Allogeneic Haematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia
Interventions
Busulfan, Clofarabine, Thymoglobulin, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 1 Interventional Results available

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

NCT03229278
View directory record Official record
Conditions
Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Bladder Carcinoma, Recurrent Classical Hodgkin Lymphoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Renal Cell Carcinoma, Stage III Bladder Cancer, Stage III Lymphoma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Renal Cell Cancer, Stage III Skin Melanoma, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Skin Melanoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Lymphoma, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Solid Neoplasm
Interventions
Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 27, 2026, 9:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis

NCT00001885
View directory record Official record
Conditions
Healthy, Pulmonary Fibrosis, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Closed-loop Glucose Control for Automated Management of Type 1 Diabetes

NCT00811317
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed-loop
Device
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 4 Interventional Results available

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

NCT02889809
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 9 Years
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
18
States / cities
Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Sep 27, 2026, 9:54 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effects of Montelukast on Occult Exercise-Induced Bronchospasm in Athletes

NCT00375232
View directory record Official record
Conditions
Exercise-Induced Bronchospasm
Interventions
Administration of montelukast or placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Alendronate to Prevent Loss of Bronchoprotection in Asthma

NCT02230332
View directory record Official record
Conditions
Asthma
Interventions
Alendronate, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Tucson, Arizona • San Francisco, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 1 Interventional

Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)

NCT00418587
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Cholecalciferol
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Results available

New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day

NCT01360021
View directory record Official record
Conditions
Asthma
Interventions
Symbicort, Budesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Huntington Beach, California • Long Beach, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Not applicable Interventional

Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults

NCT00099684
View directory record Official record
Conditions
HIV Infections
Interventions
Ezetimibe
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2012 · Synced Sep 27, 2026, 9:54 PM EDT
Not listed Not applicable Interventional

Effects of Pine Cone Extract on Serum IgE Levels in Perennial Rhinitis

NCT04024033
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
pine cone extract, placebo
Dietary Supplement · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 2 Interventional

Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease

NCT00002652
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
suramin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 27, 2026, 9:54 PM EDT
Completed No phase listed Observational

Therapeutic Research in Multiple Myeloma

NCT00572338
View directory record Official record
Conditions
Multiple Myeloma
Interventions
No drugs are involved
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
6,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Sep 27, 2026, 9:54 PM EDT
Not listed No phase listed Observational

Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis

NCT06516458
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis Relapse, Multiple Sclerosis, Relapsing-Remitting
Interventions
Camera Based Kinematic Analysis
Diagnostic Test
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Not applicable Interventional

Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia

NCT00142155
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Rituximab, monoclonal antibodies
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
30 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2011 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma

NCT00994643
View directory record Official record
Conditions
High Risk Non-Hodgkin's Lymphoma
Interventions
Rituximab, Interleukin-2
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 1 Interventional

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

NCT01149915
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, High-risk Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Advanced Myelofibrosis
Interventions
TH-302
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Not applicable Interventional

Offering Support and Electronic Resources for Care Partners of Those With Multiple Sclerosis

NCT04662008
View directory record Official record
Conditions
Multiple Sclerosis, Caregivers
Interventions
Tele-coaching, Website
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Results available

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

NCT00054717
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir, Ritonavir(r), Comparator Protease Inhibitor (CPI)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
96
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 27, 2026, 9:54 PM EDT
Active, not recruiting Not applicable Interventional

Project BIPAMS: Behavioral Intervention for Physical Activity in Multiple Sclerosis

NCT03490240
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIPAMS, WELLMS
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 64 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 27, 2026, 9:54 PM EDT
Not listed Not applicable Interventional

Evaluation of Efficacy and Tolerability of Hizentra®

NCT01354587
View directory record Official record
Conditions
Primary Immunodeficiency Disorders
Interventions
Hizentra
Drug
Lead sponsor
University of South Florida
Other
Eligibility
1 Year to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Sep 27, 2026, 9:54 PM EDT
Completed No phase listed Observational

Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS

NCT04145284
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 27, 2026, 9:54 PM EDT